A phase I trial with BMS-936559, a PD-L1-specific Ab in NSCLC, melanoma, colorectal, renal-cell, ovarian, pancreatic, gastric, and breast cancer (NCT00729664) patients resulted in an objective response rate in 9 of 52 in melanoma, in 2 of 17 in renal-cell cancer, in 5 of 49 in NSCLC, and in 1 of 17 in ovarian cancer, while drug-related adverse effects of grades 3 and 4 occurred in 9% of treated patients (144). The gene discussed is CD274; the disease is melanoma.